Table 1 Characteristics of individuals included in the study
N (%) | Total person-years of follow-up | |
|---|---|---|
Total number of cases included in analysis | 28,260 | 239,125.95 |
Female | 14,678 (51.9) | |
Age at IBD diagnosis | ||
Diagnosed ≤ 65 years | 17,662 (62.5) | |
Diagnosed ≥ 65 years | 5554 (19.7) | |
Unknowna | 5044 (17.9) | |
Rural residenceb | 4344 (15.4) | |
Mean neighbourhood income quintile | ||
Q1 | 4678 (16.7) | |
Q2 | 5420 (19.4) | |
Q3 | 5642 (20.2) | |
Q4 | 5662 (20.3) | |
Q5 | 6547 (23.4) | |
Drug group | ||
Immunomodulator Monotherapy | 4789 (16.9) | 12,141.96 |
Biologic Monotherapy | 1381 (4.9) | 3010.39 |
Combination therapy | 844 (3.0) | 1764.27 |
Mesalamine | 17,625 (62.4) | 81,128.99 |
No therapy | 28,260 (100.0) | 95,492.74 |
Systemic steroids | 14,647 (51.8) | 12,220.14 |
Type of IBD | ||
Crohn’s disease | 10,870 (38.5) | n/a |
Ulcerative colitis | 15,992 (56.6) | n/a |
IBD-type unclassified | 1398 (4.9) | n/a |